NeoMatrix Therapeutics

NeoMatrix Therapeutics, Inc. (NMT) was established by Richard A. Clark, M.D., who holds positions as a Professor of Dermatology, Biomedical Engineering, and Medicine at Stony Brook University. Following extensive research into the reasons behind ineffective wound healing, Dr. Clark and Dr. Lin identified a cell-survival peptide within the extracellular matrix (ECM) protein fibronectin (FN) that is not present in nonhealing wounds and burns. This peptide, known as NMT-cP12, fosters the survival and growth of tissue cells under challenging culture conditions, simulating unfavorable wound environments.